Natural fat compound may be basis for new class of drugs targeting obesity

September 03, 2003

Irvine, Calif. -- Researchers at the UC Irvine College of Medicine have identified how a natural fat compound works to tell the body to stop eating - a discovery that may be the basis for a new class of drugs targeting obesity and other eating disorders.

Daniele Piomelli, professor of psychiatry and pharmacology, and colleagues found that the fatty acid, called OEA (oleylethanolamide), activates its cell receptor molecules to regulate hunger and metabolism. The team also discovered that by increasing OEA levels while maintaining normal levels of these cell receptors, they could reduce appetite and weight in rodents, as well as lower their blood cholesterol and triglyceride levels.

The study appears in the Sept. 4 issue of Nature. "In earlier studies, we found that OEA can be an important regulator of eating behavior, but we didn't know how it worked," Piomelli said. "We were excited to find that OEA activates cell receptors that have already been the focus of successful drug development. This gives us hope for a new class of anti-obesity drugs based on natural chemicals."

To test the role of OEA and its receptors, Jin Fu, Silvana Gaetani, Fariba Oveisi and Jesse Lo Verme on the Piomelli team fed a high-fat diet to two groups of mice - one a group of regular mice, the other a mutant group with its OEA cell receptors genetically removed. After the mice became obese, they were treated with OEA for four weeks. Normal mice ate less and lost weight, while OEA had no effect on the group that lacked the cell receptors, suggesting that OEA only can reverse weight gain when active cell receptors are in place.

They also found that in normal mice, OEA lowered blood cholesterol and triglyceride levels by reducing levels of hunger-inducing nitric-oxide molecules. These reductions were not seen in the mutant mice group.

"This shows the receptors are not only necessary for the hunger-curbing and weight-reducing actions of OEA, but may contribute to the overall stability and maintenance of our feeding system," Piomelli said.

Piomelli believes OEA is attractive for drug development because it is a fatty acid naturally produced in the body and could be safer than current drugs when used as a long-term therapy for obesity.

"There are many drugs being tested for obesity in current clinical trials, but most don't succeed because they are not well tolerated by patients," Piomelli said. "As an endogenous compound, OEA has the potential for being much less toxic than other man-made compounds."

Nearly 30 percent of Americans are obese, according to the Centers for Disease Control, which has declared obesity an epidemic disease. The occurrence of obesity has risen by almost 60 percent since 1991. Obesity greatly increases the risk of premature death and diseases such as diabetes, heart disease, stroke and some cancers.

Piomelli's other colleagues in the study include Fernando Rodríguez de Fonseca and Antonia Serrano of the Fundacion Hospital Carlos Haya in Malaga, Spain; Barbara Di Giacomo and Giorgio Tarzia of the University of Urbino in Italy; and Anja Rosengarth and Hartmut Luecke of UCI.

The study was funded by the National Institute of Drug Abuse. UCI has filed several patents covering various aspects of this technology.

About OEA and its cell receptors

OEA belongs to a group of chemicals called fatty acid ethanolamides, fats that are produced in response to metabolic stimuli and nervous system activity. OEA is related to a neurotransmitter known as anandamide, which is similar to marijuana's active ingredient and controls a number of nervous system functions. When food is ingested, OEA is manufactured in the small intestine, where it finds nerve endings that carry its hunger-curbing message to the brain. The Piomelli team found that OEA compounds bind with a member of the peroxisome proliferatory-activated receptor (PPAR) family. OEA specifically activates the PPAR-alpha receptor, which sets off the body's metabolism of fats.
-end-
UCI maintains an online directory of faculty available as experts to the media. To access, visit: http://www.today.uci.edu/experts.

University of California - Irvine

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.